

Cholesterol-lowering effect of hydroxychloroquine in p Reversal of deleterious effects of steroids on lipids

American Journal of Medicine

89, 322-326

DOI: [10.1016/0002-9343\(90\)90345-e](https://doi.org/10.1016/0002-9343(90)90345-e)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Risk factors for coronary artery disease in patients with systemic lupus erythematosus. American Journal of Medicine, 1992, 93, 513-519.	0.6	557
2	Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein a1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1993, 36, 1566-1574.	6.7	81
3	Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1993, 42, 415-419.	1.5	26
4	The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE. Lupus, 1993, 2, 13-15.	0.8	86
5	Systemic lupus erythematosus ? disease management. Seminars in Immunopathology, 1994, 16, 281-94.	4.0	3
6	Short-term effects of mepacrine on serum lipids, lipoproteins, and apolipoproteins in patients with non-insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1994, 43, 131-134.	1.5	4
7	Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. American Journal of Medicine, 1994, 96, 254-259.	0.6	291
8	Antimalarial Drugs. BioDrugs, 1995, 4, 219-234.	0.7	7
9	Biochemical characterization of ADP-ribose polymer metabolism in SLE. Lupus, 1996, 5, 14-21.	0.8	140
10	The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus, 1996, 5, 59-64.	0.8	37
11	Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus, 1996, 5, 16-22.	0.8	202
12	The use of antimalarials in combination with other disease modifying agents in RA – the British experience. Lupus, 1996, 5, 50-58.	0.8	6
13	Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus, 1996, 5, 237-241.	0.8	118
14	Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 1997, 56, 374-377.	0.5	115
15	An Overview of the Treatment of Childhood SLE. Scandinavian Journal of Rheumatology, 1997, 26, 241-246.	0.6	26
16	Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus, 1997, 6, 533-539.	0.8	241
17	Dyslipidaemia and rheumatoid arthritis. Annals of the Rheumatic Diseases, 1997, 56, 341-342.	0.5	75
18	7 Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Bailliere's Clinical Rheumatology, 1998, 12, 495-510.	1.0	22

#	ARTICLE	IF	CITATIONS
19	Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 198-203.	1.5	30
20	Hydroxychloroquine: past, present, future. <i>Lupus</i> , 1998, 7, 65-67.	0.8	34
21	MANAGEMENT OF LIPID DISORDERS. <i>Rheumatic Disease Clinics of North America</i> , 1999, 25, 507-520.	0.8	2
22	The use of antimalarials in dermatology. <i>Journal of Dermatological Treatment</i> , 2000, 11, 185-194.	1.1	4
23	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000, 2, 19-23.	2.1	34
24	Accelerated atheroma in lupusâ€™background. <i>Lupus</i> , 2000, 9, 161-165.	0.8	48
25	How accelerated atherosclerosis in SLE has changed our management of the disorder. <i>Lupus</i> , 2000, 9, 228-231.	0.8	21
26	Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. <i>Lupus</i> , 2000, 9, 413-416.	0.8	34
27	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 257-278.	0.8	154
28	ANTIMALARIALS. <i>Dermatologic Clinics</i> , 2001, 19, 147-160.	1.0	67
29	Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. <i>Lupus</i> , 2001, 10, 359-363.	0.8	40
30	Antimalarialsâ€™the â€™realâ€™ advance in lupus. <i>Lupus</i> , 2001, 10, 385-387.	0.8	73
31	Antimalarial therapy: a panacea for mild lupus?. <i>Lupus</i> , 2001, 10, 148-151.	0.8	36
32	Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. <i>Lupus</i> , 2002, 11, 71-81.	0.8	64
33	Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. <i>Lupus</i> , 2002, 11, 356-361.	0.8	121
35	Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis?. <i>Arthritis and Rheumatism</i> , 2002, 46, 862-873.	6.7	556
36	Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB x NZW) F1 mice. <i>Journal of Clinical Immunology</i> , 2003, 23, 23-33.	2.0	26
37	Polymorphism of the Î²3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine. <i>Rheumatology International</i> , 2003, 23, 99-103.	1.5	9

#	ARTICLE	IF	CITATIONS
38	Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , 2003, 48, 3159-3167.	6.7	327
39	Treatment of Lupus Nephritis. <i>Drugs</i> , 2003, 63, 257-274.	4.9	12
40	Tackling ischaemic heart disease in rheumatoid arthritis. <i>British Journal of Rheumatology</i> , 2003, 42, 607-613.	2.5	143
41	Cardiovascular risk in systemic lupus erythematosus—evidence of increased oxidative stress and dyslipidaemia. <i>British Journal of Rheumatology</i> , 2003, 42, 758-762.	2.5	80
42	Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis. <i>Circulation</i> , 2003, 107, 1303-1307.	1.6	1,117
43	Cardiac Involvement in Systemic Lupus Erythematosus. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, 1, 145-161.	0.1	1
44	Cardiac Involvement in Rheumatoid Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, , 121-143.	0.1	1
45	The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 961-968.	0.8	10
46	Prevention of cardiovascular disease in systemic lupus erythematosus—proposed guidelines for risk factor management. <i>British Journal of Rheumatology</i> , 2004, 43, 7-12.	2.5	139
47	Serum oxidized low-density lipoproteins in rheumatoid arthritis. <i>Rheumatology International</i> , 2004, 24, 230-233.	1.5	48
48	Laboratory Features of Cutaneous Lupus Erythematosus. , 2005, , 311-322.		3
49	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. <i>Arthritis and Rheumatism</i> , 2005, 52, 1473-1480.	6.7	324
50	Atherogenesis and autoimmune disease: the model of lupus. <i>Lupus</i> , 2005, 14, 687-690.	0.8	43
51	Disease modification and cardiovascular risk reduction: two sides of the same coin?. <i>Rheumatology</i> , 2005, 44, 1473-1482.	0.9	69
52	The management of pediatric systemic lupus erythematosus. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 82-92.	3.2	13
53	“Not only” but also™: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. <i>Rheumatology</i> , 2005, 44, 1492-1502.	0.9	244
55	CHRONIC ARTHRITIS IN CHILDHOOD. , 2005, , 206-260.		54
56	Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. <i>Arthritis Research and Therapy</i> , 2006, 8, R151.	1.6	214

#	ARTICLE	IF	CITATIONS
58	Artrite reumatóide e doenças cardiovasculares. Revista Brasileira De Reumatologia, 2006, 46, 60-66.	0.8	9
59	Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy. Clinical Rheumatology, 2006, 25, 515-519.	1.0	10
60	Prevention of cardiovascular disease in patients with rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2006, 20, 741-756.	1.4	6
61	Premature Atherosclerosis in Systemic Lupus Erythematosus: Pathogenesis and Therapeutic Considerations. Hong Kong Journal of Nephrology, 2006, 8, 48-54.	0.0	2
62	Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2006, 13, 203-208.	3.3	63
63	Antiphospholipid (Hughes) syndrome and atheroma. Lupus, 2006, 15, 55-58.	0.8	5
64	The influence of other drugs on coronary heart disease (CHD) risk in systemic lupus erythematosus. Lupus, 2006, 15, 23-26.	0.8	2
65	Childhood Systemic Lupus Erythematosus: New and Old Treatments. Current Pediatric Reviews, 2006, 2, 165-171.	0.4	0
66	Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). Lupus, 2006, 15, 700-704.	0.8	7
67	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Annals of the Rheumatic Diseases, 2006, 65, 785-790.	0.5	63
68	Management of Vasculopathy in Connective Tissue Disease. Current Rheumatology Reviews, 2006, 2, 269-278.	0.4	0
69	Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus, 2006, 15, 577-583.	0.8	351
70	The heart-joints connection: atherosclerosis and inflammation. Expert Review of Clinical Immunology, 2007, 3, 517-529.	1.3	0
71	Efficacy and Safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial - an Indian experience. Current Medical Research and Opinion, 2007, 23, 2227-2234.	0.9	18
72	Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: A study with a questionnaire. Lupus, 2007, 16, 701-706.	0.8	23
73	Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus, 2007, 16, 273-278.	0.8	57
74	Athérome et lupus érythémateux systémique. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 1235-1239.	0.0	0
75	New concepts in antimalarial use and mode of action in dermatology. Dermatologic Therapy, 2007, 20, 160-174.	0.8	234

#	ARTICLE	IF	CITATIONS
76	Systemic lupus erythematosus: modern strategies for management – a moving target. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 971-987.	1.4	13
77	Atheroma and systemic lupus erythematosus. <i>Joint Bone Spine</i> , 2007, 74, 566-570.	0.8	20
78	Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors. <i>Archives of Drug Information</i> , 2008, 1, 23-28.	1.6	9
80	Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: Plasma concentrations and relationship to inflammation. <i>Clinica Chimica Acta</i> , 2008, 390, 67-71.	0.5	52
82	Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. <i>Lupus</i> , 2008, 17, 849-859.	0.8	85
83	Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. <i>Lupus</i> , 2008, 17, 114-123.	0.8	23
84	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , 2008, 17, 271-273.	0.8	63
85	Lupus Nephritis. , 2008, , 329-342.		0
86	Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. <i>Lupus</i> , 2009, 18, 1019-1025.	0.8	62
87	Poor Outcomes After Acute Myocardial Infarction in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 570-575.	1.0	41
88	Cardiovascular risk assessment and treatment in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 481-494.	1.4	32
89	Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. <i>Arthritis and Rheumatism</i> , 2009, 61, 1396-1402.	6.7	228
90	Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?. <i>Arthritis and Rheumatism</i> , 2009, 61, 1284-1286.	6.7	4
91	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009, 11, 248-254.	2.1	34
92	The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. <i>Clinical Biochemistry</i> , 2009, 42, 1352-1357.	0.8	11
94	Dyslipidaemia in Rheumatoid Arthritis: The Role of Inflammation, Drugs, Lifestyle and Genetic Factors. <i>Current Vascular Pharmacology</i> , 2010, 8, 301-326.	0.8	109
95	Lupus Registries: Evolution and Challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 224-245.	1.6	16
96	AJC Editor's Consensus: Rheumatoid Arthritis and Atherosclerotic Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2010, 106, 442-447.	0.7	19

#	ARTICLE	IF	CITATIONS
97	Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2010, 99, 967-974.	0.7	34
98	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 163-175.	1.1	52
99	Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 683-688.	0.5	135
100	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010, 12, R125.	1.6	24
101	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R156.	1.6	71
102	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2011, 14, 1-5.	0.9	9
103	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 705-714.	1.0	80
104	Antimalarials and SLE. , 2011, , 1061-1081.		2
105	Antimaláricos e perfil lipídico em pacientes com lúpus eritematoso sistêmico. <i>Revista Brasileira De Reumatologia</i> , 2011, 51, 385-387.	0.8	9
107	Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2011, 63, 530-534.	1.5	124
108	Are Lipid Ratios Less Susceptible to Change With Systemic Inflammation Than Individual Lipid Components in Patients With Rheumatoid Arthritis?. <i>Angiology</i> , 2011, 62, 167-175.	0.8	60
109	Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 13-26.	0.2	68
110	Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective. <i>Arthritis</i> , 2012, 2012, 1-15.	2.0	57
111	Accelerated atherosclerosis in systemic lupus erythematosus: mechanisms and prevention approaches. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 527-539.	0.3	18
112	Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. <i>Lupus</i> , 2012, 21, 1178-1182.	0.8	106
113	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. <i>Internal Medicine Journal</i> , 2012, 42, 968-978.	0.5	86
114	Cardiovascular Involvement in Systemic Lupus Erythematosus. , 2012, , .		1
115	Consenso 2012 da Sociedade Brasileira de Reumatologia sobre o manejo de comorbidades em pacientes com artrite reumatoide. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 483-495.	0.8	13

#	ARTICLE	IF	CITATIONS
116	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. <i>Nature Reviews Rheumatology</i> , 2012, 8, 522-533.	3.5	176
117	Hydroxychloroquine: From Malaria to Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 145-153.	2.9	465
118	Is there an effective treatment for late-onset systemic lupus erythematosus?. <i>Aging Health</i> , 2013, 9, 437-450.	0.3	0
119	Antimalarial Medications. , 2013, , 601-608.		3
120	Measuring disease activity and severity in clinical trials and the clinic: same or different?. <i>Arthritis Research and Therapy</i> , 2013, 15, .	1.6	2
121	Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. <i>Lupus</i> , 2013, 22, 519-526.	0.8	16
122	Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 45-52.	0.9	148
123	The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders. <i>Current Rheumatology Reviews</i> , 2013, 9, 45-62.	0.4	41
125	Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications. <i>Arthritis Care and Research</i> , 2014, 66, 1619-1626.	1.5	60
126	Effect of Hydroxychloroquine on the Lipid Profile of Patients with Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2014, 41, 902-908.	1.0	18
127	Pharmacology of Chloroquine and Hydroxychloroquine. , 2014, , 35-63.		94
129	Chronic Hydroxychloroquine Improves Endothelial Dysfunction and Protects Kidney in a Mouse Model of Systemic Lupus Erythematosus. <i>Hypertension</i> , 2014, 64, 330-337.	1.3	110
130	The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). <i>Lupus</i> , 2014, 23, 1014-1022.	0.8	9
131	A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2014, 5, 77-85.	1.4	71
133	Hydroxychloroquine: A multifaceted treatment in lupus. <i>Presse Medicale</i> , 2014, 43, e167-e180.	0.8	153
134	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 277.	1.6	55
135	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2176-2184.	2.9	118
136	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 358-362.	2.5	101

#	ARTICLE	IF	CITATIONS
137	Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. <i>Rheumatology International</i> , 2015, 35, 1059-1067.	1.5	19
138	Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. <i>Current Medical Research and Opinion</i> , 2015, 31, 2105-2117.	0.9	28
139	Disease-Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study. <i>Arthritis Care and Research</i> , 2015, 67, 457-466.	1.5	28
140	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.5	70
141	Value of Antimalarial Drugs in the Treatment of Lupus. , 2016, , 515-520.		0
142	Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, pww035.	1.4	31
143	Anti-malarials: Are There Benefits Beyond Mild Disease?. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 1-12.	0.6	6
144	Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. <i>Drugs</i> , 2016, 76, 459-483.	4.9	150
145	Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. <i>Lupus</i> , 2016, 25, 177-184.	0.8	47
146	Cardiac Involvement in Systemic Lupus Erythematosus. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 265-293.	0.1	0
147	Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 144-148.	0.5	19
148	An update on diet and nutritional factors in systemic lupus erythematosus management. <i>Nutrition Research Reviews</i> , 2017, 30, 118-137.	2.1	62
149	Clinical significance of lipid profile in systemic lupus erythematosus patients: Relation to disease activity and therapeutic potential of drugs. <i>Egyptian Rheumatologist</i> , 2017, 39, 93-98.	0.5	9
150	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <i>Immunologic Research</i> , 2017, 65, 17-24.	1.3	97
151	Comorbidities and related factors in rheumatoid arthritis patients of south India- Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study. <i>Reumatismo</i> , 2017, 69, 47.	0.4	11
152	Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. <i>International Journal of Clinical Practice</i> , 2018, 72, e13095.	0.8	22
153	Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 84-92.	0.9	34
154	The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. <i>Oncotarget</i> , 2018, 9, 6615-6622.	0.8	25

#	ARTICLE	IF	CITATIONS
155	Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 42.	2.1	23
156	Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2018, 45, 1462-1476.	1.0	38
157	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <i>Clinical Drug Investigation</i> , 2018, 38, 653-671.	1.1	226
158	Incidence of cardiovascular risk factors in female patients with systemic lupus erythematosus: a 3-year follow-up cohort. <i>Lupus</i> , 2018, 27, 1790-1798.	0.8	8
159	NMR-Based Serum Metabolomics Reveals Reprogramming of Lipid Dysregulation Following Cyclophosphamide-Based Induction Therapy in Lupus Nephritis. <i>Journal of Proteome Research</i> , 2018, 17, 2440-2448.	1.8	27
160	Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, 1743-1751.	0.9	35
161	Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients. <i>Medicine (United States)</i> , 2019, 98, e15030.	0.4	18
162	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. <i>Autoimmunity Reviews</i> , 2019, 18, 317-324.	2.5	7
163	Antimalarial Medications. , 2019, , 650-660.		0
164	Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 39-49.	1.1	23
165	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. <i>Molecules</i> , 2020, 25, 5318.	1.7	9
166	The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. <i>Pharmacological Research</i> , 2020, 158, 104904.	3.1	106
167	Covid-19 treatment update: follow the scientific evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 43-53.	1.0	45
168	Value of antimalarial drugs in the treatment of lupus. , 2021, , 591-595.		1
169	Autoimmune connective tissue diseases in the COVID-19 pandemic. <i>Clinics in Dermatology</i> , 2021, 39, 56-63.	0.8	8
170	Effect of Hydroxychloroquine on Lipid Levels: A Systematic Review and Metaanalysis. <i>Current Pharmaceutical Design</i> , 2021, 27, 4133-4139.	0.9	5
171	Effects of Hydroxychloroquine on endothelial function in elderly with sleep apnea (HOLD): study protocol for a randomized clinical trial. <i>Trials</i> , 2021, 22, 638.	0.7	1
172	Antimalarial drugs (and lupus). , 2021, , 601-609.		0

#	ARTICLE	IF	CITATIONS
173	Molekulare Grundlagen der Behandlung rheumatischer Erkrankungen. , 2003, , 237-253.		1
174	Atherosclerosis in Systemic Lupus Erythematosus. , 2001, , 255-265.		5
176	ANTIMALARIAL AGENTS AND LUPUS. Rheumatic Disease Clinics of North America, 1994, 20, 243-263.	0.8	122
177	Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Current Opinion in Rheumatology, 2001, 13, 341-344.	2.0	68
178	The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. Current Opinion in Rheumatology, 2021, 33, 211-218.	2.0	9
179	Hydroxychloroquine: a diabetic drug in disguise?. BMJ Case Reports, 2009, 2009, bcr0820080654-bcr0820080654.	0.2	12
180	Rheumatoid arthritis: influence of inflammation and anti-inflammatory therapy on cardiovascular risk factors. Meditsinskiy Sovet, 2020, , 32-44.	0.1	2
181	Antimalarial Drugs in Systemic Lupus Erythematosus. Drug Safety, 2001, 24, 1055-1063.	1.4	42
182	Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. European Journal of Rheumatology, 2020, 7, S117-S120.	1.3	28
183	Dyslipoproteinemia and Premature Atherosclerosis in the Pediatric Rheumatic Disease. , 2001, , 329-333.		0
185	Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk. , 2011, , 17-25.		0
186	Artrite reumatoide: por que tratar apenas a artrite, sabendo que comorbidades são comuns e determinam morbidade e mortalidade?. Revista Brasileira De Reumatologia, 2012, 52, 472-473.	0.8	0
187	Pharmacotherapy in Systemic Lupus Erythematosus. Current Rheumatology Reviews, 2012, 8, 166-179.	0.4	0
188	Systemic lupus erythematosus " disease management. , 1995, , 151-164.		0
189	Lupus Nephritis. , 2016, , 759-780.		0
190	AB0392...THE EFFECT OF HYDROXYCHLOROQUINE ON THE RISK FACTORS FOR ATHEROSCLEROSIS DEVELOPMENT. Annals of the Rheumatic Diseases, 2020, 79, 1496.3-1496.	0.5	1
191	CHLOROQUINE AND HYDROXYCHLOROQUINE: A MAJOR BREAKTHROUGH FOR COVID-19. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 1-5.	0.3	0
192	Uncoupling Protein 2 as genetic risk factor for systemic lupus erythematosus: association with malondialdehyde levels and intima media thickness. Minerva Cardioangiologica, 2020, 68, 609-618.	1.2	3

#	ARTICLE	IF	CITATIONS
193	Glycemic efficacy and safety of hydroxychloroquine in type 2 diabetes mellitus: A systematic review and meta.analysis of relevance amid the COVID-19 pandemic. International Journal of Noncommunicable Diseases, 2020, 5, 184.	0.4	3
194	Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis. Cureus, 2021, 13, e19308.	0.2	6
195	Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. , 2018, 2, .		19
196	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110730.	1.2	52
197	Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2022, 9, e000681.	1.1	2
199	Role of Lipoprotein Levels and Function in Atherosclerosis Associated with Autoimmune Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2023, 49, 151-163.	0.8	1
200	Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. Pharmaceutics, 2022, 14, 2551.	2.0	4
201	Stroke and Systemic Lupus Erythematosus: A Review. European Medical Journal Rheumatology, 0, , 100-107.	0.0	3
202	Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2023, 10, e000841.	1.1	6
204	Lupus Nephritis. , 2023, , 737-763.		0
205	Hydroxychloroquine in nephrology: current status and future directions. Journal of Nephrology, 2023, 36, 2191-2208.	0.9	1